Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A molecular subtype of glioblastoma characterized by the presence of NF1 mutations.
Biomarker and diagnostic research for mesenchymal glioblastoma has been reported in the published literature.
No clinical trials have been registered for mesenchymal glioblastoma.
127 publications have been identified in PubMed for mesenchymal glioblastoma. Research spans Basic Science / Preclinical (71%), Gene Therapy / Novel Therapeutics (13%), and Diagnostic / Biomarker (8%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 90 | 71% |
Data assembled from 2 of 12 sources · Last updated Oct 3, 2026, 1:44 PM UTC
16 |
13% |
Testing and diagnosis research | 10 | 8% |
Research summaries | 5 | 4% |
Clinical study results | 3 | 2% |
Disease patterns and progression | 3 | 2% |
Hao Y (2026). [PMID: 41750122](https://pubmed.ncbi.nlm.nih.gov/41750122/). *Brain Sci*. [Epidemiology / Natural History]
Rancati S (2026). [PMID: 42104024](https://pubmed.ncbi.nlm.nih.gov/42104024/). *BJC Rep*. [Basic Science / Preclinical]
Vishnoi M (2026). [PMID: 41490939](https://pubmed.ncbi.nlm.nih.gov/41490939/). *Communications biology*. [Basic Science / Preclinical]
Weng L (2026). [PMID: 41619772](https://pubmed.ncbi.nlm.nih.gov/41619772/). *Neuro-oncology*. [Basic Science / Preclinical]
Xiong Z (2026). [PMID: 41436600](https://pubmed.ncbi.nlm.nih.gov/41436600/). *Cellular & molecular immunology*. [Diagnostic / Biomarker]
Cheng HS (2026). [PMID: 41502293](https://pubmed.ncbi.nlm.nih.gov/41502293/). *Curr Opin Clin Nutr Metab Care*. [Basic Science / Preclinical]
Ghaemi B (2026). [PMID: 42127174](https://pubmed.ncbi.nlm.nih.gov/42127174/). *Sci Adv*. [Diagnostic / Biomarker]
Zhang J (2026). [PMID: 40973181](https://pubmed.ncbi.nlm.nih.gov/40973181/). *Neuro-oncology*. [Basic Science / Preclinical]
Silverbush D (2026). [PMID: 41499453](https://pubmed.ncbi.nlm.nih.gov/41499453/). *Neuro-oncology*. [Review / Meta-Analysis]
McManis A (2026). [PMID: 41903119](https://pubmed.ncbi.nlm.nih.gov/41903119/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
AI-curated news mentioning mesenchymal glioblastoma
Updated Sep 10, 2026
Sapanisertib shows promise for treating rare mTOR-driven disorders, with potential applications in various cancers including bladder and ovarian cancer. Successful late-stage clinical development could unlock orphan-drug incentives and enhance adoption in specialized treatment centers.
A study from EORTC 1419 (ETERNITY) examines neurocognitive functioning in long-term survivors of glioblastoma and astrocytoma, providing insights into the cognitive impacts of these CNS tumors. The findings contribute to understanding the long-term effects of these aggressive cancers on patient quality of life.
A case study highlights the successful multimodal treatment of a rare dual fungal brain abscess, which mimicked glioblastoma in an immunocompetent patient. This research contributes to the understanding of differential diagnoses in brain lesions.
Recent research highlights the development of magneto-NIR-II-programmed cascade nanozymes that facilitate blood-brain barrier translocation and enhance autophagic resistance in glioblastoma. This innovative approach could pave the way for more effective treatments targeting this aggressive brain tumor.